Jose Orlando Nicolas MD and Ira Inductivo-Yu MD*
Division of Internal Medicine, National Kidney and Transplant Institute, Manila, Philippines
*Corresponding Author: Ira Inductivo-Yu MD, Division of Internal Medicine, National Kidney and Transplant Institute, Manila, Philippines.
Received: March 16, 2023; Published: March 20, 2023
Background: Thrombocytopenia is commonly found among patients with liver cirrhosis. It complicates treatment of patients requiring an invasive procedure as part of their routine clinical care. An important clinical question is whether there is a need for a platelet-stimulating growth factor or thrombopoietin receptor agonist among patients with liver cirrhosis who have thrombocytopenia.
Case Summary: This paper discusses the profile of three patients with thrombocytopenia and liver cirrhosis who received Eltrombopag prior to invasive procedures and one patient in the control of hemorrhagic stroke expansion. Eltrombopag was given at doses of 25 mg to 50 mg daily for two to three weeks, except one patient who was maintained for more than a year. Bleeding complications were prevented in all patients, with no adverse events seen during and post treatment.
Conclusion: Treatment with eltrombopag is an effective and safe approach to increase platelet counts in thrombocytopenic cirrhotic patients
Keywords: Case Series; Eltrombopag; Liver Cirrhosis; Thrombocytopenia; Platelet Transfusion
Citation: Jose Orlando Nicolas MD and Ira Inductivo-Yu MD. “Splenic Artery Aneurysm. A Rare Entity Case Report". Acta Scientific Gastrointestinal Disorders 6.4 (2023): 18-22.
Copyright: © 2023 Jose Orlando Nicolas MD and Ira Inductivo-Yu MD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.